TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
An October 20 endocrinology roundup highlighted several separate findings: about one-quarter of active-duty Army men had a single morning testosterone reading below 300 ng/dL, and a CDC report described menopause symptoms and prescription treatment use. A JAMA Network Open analysis of Reddit posts about unapproved retatrutide found users frequently mentioned several symptoms, but social-media reports cannot establish how often side effects occur or whether the drug caused them.
An October 20 endocrinology roundup reported that about one-quarter of active-duty U.S. Army men had a single morning testosterone reading below 300 ng/dL, while separate findings covered menopause treatment and retatrutide-related Reddit posts. The items summarize distinct studies and reports; they do not establish that one low test diagnoses a hormone disorder or that social-media posts measure a drug’s side-effect rate.
The Army finding, attributed to research published in JAMA, used a testosterone concentration below 300 ng/dL as a commonly used cutoff. The reported result was based on a single morning measurement. The roundup does not provide the study’s sample size, participant characteristics beyond active-duty Army men, or further clinical details.
A CDC report found that nearly half of U.S. women ages 40 to 60 reported menopausal symptoms in 2025, and 15.6% of women in that age group were taking prescription medication for those symptoms. The roundup also cited a post-hoc analysis reported by Novo Nordisk: the company said its investigational semaglutide-cagrilintide combination was associated with an average 25% weight loss among women in a phase III trial, with similar results across pre-, peri- and postmenopausal groups.
Separately, an analysis in JAMA Network Open examined Reddit users’ reports of taking retatrutide, an unapproved weight-loss drug. Frequently mentioned adverse-event terms included appetite increases, fatigue, increased energy, insomnia, increased heart rate and muscle-related symptoms. These are terms reported in posts, not confirmed diagnoses or evidence of how often symptoms occur among all users.
What the Findings Can Tell Patients
Together, the reports touch on hormone testing, menopause care and weight-loss treatments, areas where patients may encounter broad claims online or in clinical discussions. The Army result may prompt questions about screening, but a single reading below a threshold does not by itself show how many people have a diagnosed condition or need treatment. Clinical interpretation depends on the full evaluation, details not supplied in the roundup.
The menopause figures offer a snapshot of reported symptoms and prescription use among women ages 40 to 60, rather than a measure of treatment effectiveness or unmet need. The Reddit analysis gives researchers a view of what some people discuss after using retatrutide, but it cannot determine causation or prevalence. For readers, the distinction matters: online reports can flag experiences for further study, but they are not a substitute for safety data from controlled trials.
Three Separate Endocrine Reports
The material appeared as a brief endocrinology news roundup, not as one study linking testosterone, menopause and weight-loss drugs. Its items drew on different sources, including JAMA, a CDC report, JAMA Network Open and company statements. The research designs and populations therefore differ, and the figures should not be combined into a single estimate or conclusion.
The roundup also noted other developments: a meta-analysis of phase III trial data linked greater weight reduction from GLP-1 receptor agonists and newer multi-hormone receptor medicines with larger blood-pressure reductions; Walmart planned to cover more than 250 prescription drugs at no cost for employees in 2027, including some insulins and diabetes GLP-1 drugs; and Verdiva Bio ended a phase II study of an oral GLP-1 candidate, citing “market evolution.” Those items provide industry and research context, but do not change what the three headline findings show.
“A testosterone concentration under 300 ng/dL is a commonly used cutoff for low testosterone.”
— MedPage Today roundup, citing the Army testosterone study in JAMA
Limits of the Available Evidence
The roundup does not give the Army study’s sample size, the number of men with repeat low readings, or whether participants had symptoms or a clinical diagnosis. It also does not explain how the CDC report defined menopausal symptoms or prescription medication use. Those details are needed to interpret the findings beyond the reported percentages.
For retatrutide, the number and selection of Reddit posts, the users’ doses, and whether reported symptoms were medically verified are not provided. Because the drug is unapproved and the analysis relies on self-reports, the listed terms cannot establish its safety profile or the frequency of side effects. The company’s menopause-related weight-loss analysis is also described as post hoc; the roundup does not provide the full results or trial methods.
Awaiting Full Study Details
Readers will need the underlying publications and reports for fuller information on methods, participant groups and limitations. Further clinical studies would be needed to test whether the patterns seen in Reddit reports reflect drug-related effects and to assess retatrutide’s safety. The semaglutide-cagrilintide findings likewise require review of the full trial analysis and any subsequent regulatory updates.
For now, the roundup’s figures are best read as separate research and reporting developments, not guidance to start or stop treatment. No additional study releases or regulatory decisions were specified in the source material.
Key Questions
Does one testosterone reading below 300 ng/dL mean a soldier has low testosterone?
No. The roundup reports that about one-quarter had a single morning reading below a commonly used cutoff. It does not say that one measurement alone establishes a diagnosis.
What did the CDC report say about menopause?
Nearly half of U.S. women ages 40 to 60 reported menopausal symptoms in 2025, and 15.6% of that age group were taking prescription medication for those symptoms.
Do the Reddit posts show how common retatrutide side effects are?
No. The analysis counted symptom terms in posts by Reddit users who reported taking retatrutide. It does not establish side-effect rates, causation or medical verification.
Is retatrutide approved for weight loss?
The roundup describes retatrutide as an unapproved weight-loss drug. It does not report a regulatory approval or a decision date.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
